A BLIND CONTROLLED TRIAL OF DEXTRAN 40 IN THE TREATMENT OF ISCHÆMIC STROKE

Abstract

A blind controlled trial of dextran 40 in ischaemic stroke is reported. In the treated group mortality in the acute stage in patients with severe strokes was significantly reduced but survivors were severely disabled and six months later no significant benefit could be detected. In less severe strokes no effect of treatment was found. It is concluded that the action of dextran 40 in reducing acute mortality probably lay in preventing or reversing cerebral swelling but no evidence of the expected action in reducing the area of infarction following improved blood flow was found. The importance of extending assessment beyond the two weeks customary in therapeutic trials in stroke is emphasized.

Keywords

MedicineStroke (engine)Randomized controlled trialIschaemic strokeIschemiaClinical trialInfarctionAcute strokeDextranAnesthesiaInternal medicineSurgeryMyocardial infarctionTissue plasminogen activator

Affiliated Institutions

University of Oxford GB

Related Publications

CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.

There are two major trials of aspirin in acute ischaemic stroke. Taken together, CAST and the similarly large IST show reliably that aspirin started early in hospital produces a...

1997 PubMed 253 citations

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Martin Dennis

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine ha...

1996 The Lancet 2732 citations

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

<h3>Abstract</h3> <b>Objective</b>: To determine the effects of “prolonged” antiplatelet therapy (that is, given for one month or more) on “vascular events” (non-fatal myocardia...

1994 BMJ 3110 citations

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.

Several studies have established the value of anticoagulation for primary prevention of thromboembolic events in patients with non-rheumatic atrial fibrillation (NRAF). However,...

1993 PubMed 333 citations

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

James Shepherd , Gerard J. Blauw , Michael Murphy +17 more

Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Ou...

2002 The Lancet 3358 citations

Publication Info

Year: 1976
Type: article
Volume: 99
Issue: 2
Pages: 193-206
Citations: 97
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A BLIND CONTROLLED TRIAL OF DEXTRAN 40 IN THE TREATMENT OF ISCHÆMIC STROKE

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    W.B. Matthews, 
                                
                                    J.M. Oxbury, 
                                
                                    Keith Grainger
                                
                                et al.
                            
                            (1976). 
                            A BLIND CONTROLLED TRIAL OF DEXTRAN 40 IN THE TREATMENT OF ISCHÆMIC STROKE. 
                            Brain
                            , 99
                            (2)
                            , 193-206.
                            https://doi.org/10.1093/brain/99.2.193
                        

Identifiers

DOI: 10.1093/brain/99.2.193